The National Institute for Clinical Excellence (NICE) currently do not recommend routine antenatal screening for CMV. This because there is currently no way of preventing transmission of the virus to an unborn baby and no way to determine whether a baby will be born with problems.
A study in the US is testing whether CMV Immunoglobulin therapy may reduce the risk of transmission when given to pregnant women experiencing a primary CMV infection. This follows mixed results from previous studies of immunoglobulin therapy in Italy. The US study is due to report in 2019.
In the meantime, CMV Action is working with researchers to try and secure funding for a pilot to test out how CMV screening in pregnancy could work within the NHS.
We will continue to campaign for change.